Monday, 23 September 2019

Takeda diabetes drug gets China's import license

06 August 2013 | News | By BioSpectrum Bureau

Takeda has been issued an Import Drug License (IDL) by the China Food and Drug Administration for its type 2 diabetes drug Nesina

Takeda has been issued an Import Drug License (IDL) by the China Food and Drug Administration for its type 2 diabetes drug Nesina

Singapore: China's State Food and Drug Administration (SFDA) issued an Import Drug License (IDL) for Takeda's type 2 diabetes drug Nesina (alogliptin).

Orally administered dipeptidyl peptidase-4 inhibitor (DPP-4i), Nesina has been designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide).

The drug was approved and launched in Japan in 2010 and it is now available in the US as a monotherapy and also in fixed-dose combinations with metformin (Kazano) and pioglitazone (Oseni).

The US FDA approved the medication in January this year, for the treatment of type 2 diabetes in adults, as adjuncts to diet and exercise.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls